Cargando…

Bleomycin Sclerotherapy in Massive Macrocystic Lymphatic Malformation: Minimal Complications with Maximum Results

INTRODUCTION: Cystic lymphangioma (CL) is a multiloculated congenital malformation of the lymphatic system occurring in approximately 1 in 6,000–12,000 births, and it mostly presents at birth. The CL is of a variable size and it can be found at any age and in any part of the body. This study was car...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhatnagar, Ankur, Neyaz, Zafar, Singh, Brajesh, Mishra, Ashwani, Yusuf, Upadyayaya, Vijai Datta, Kumar, Basant
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8061645/
https://www.ncbi.nlm.nih.gov/pubmed/33911413
http://dx.doi.org/10.4103/JCAS.JCAS_108_20
_version_ 1783681608451096576
author Bhatnagar, Ankur
Neyaz, Zafar
Singh, Brajesh
Mishra, Ashwani
Yusuf,
Upadyayaya, Vijai Datta
Kumar, Basant
author_facet Bhatnagar, Ankur
Neyaz, Zafar
Singh, Brajesh
Mishra, Ashwani
Yusuf,
Upadyayaya, Vijai Datta
Kumar, Basant
author_sort Bhatnagar, Ankur
collection PubMed
description INTRODUCTION: Cystic lymphangioma (CL) is a multiloculated congenital malformation of the lymphatic system occurring in approximately 1 in 6,000–12,000 births, and it mostly presents at birth. The CL is of a variable size and it can be found at any age and in any part of the body. This study was carried out to observe the effect of intralesional aqueous bleomycin on giant CL presenting in adult and pediatric cases. MATERIALS AND METHODS: This is an observational study conducted in the department of pediatric surgery and plastic surgery from January 2012 to January 2020. All the diagnosed cases of lymphangioma measuring more than 5 cm in size and managed during this period were reviewed. The cases who had lesions with a vascular component or who had any history of previous surgery or any form of treatment were excluded from the study. A total of 19 cases were included in the study. The primary mode of management of CL at the present center is intralesional bleomycin sclerotherapy (IBS). This is the standard protocol followed at our center to treat the cases with CL. Relevant demographic and clinical data of all the included patients were collected on a structured proforma, and data were analyzed. RESULT: Four cases had a favorable outcome in a single session, seven cases showed a favorable response after the second session, and three cases showed a favorable response after the third session. Two cases showed a partial response even after the fourth session and were considered nonresponders, one of whom was operated on and the other who was satisfied with a partial response and was not willing to undergo surgical excision. No major complications were observed in the present series. A few cases developed mild pain with or without fever, but none of them required hospitalization. CONCLUSION: Intralesional bleomycin sclerotherapy (IBS) is a safe, effective, and economical treatment option for the management of large cystic lymphangiomas and it avoids surgery-related complications. Level of Study: IV evidence study Type of Study: Retrospective observational study
format Online
Article
Text
id pubmed-8061645
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-80616452021-04-27 Bleomycin Sclerotherapy in Massive Macrocystic Lymphatic Malformation: Minimal Complications with Maximum Results Bhatnagar, Ankur Neyaz, Zafar Singh, Brajesh Mishra, Ashwani Yusuf, Upadyayaya, Vijai Datta Kumar, Basant J Cutan Aesthet Surg Original Article INTRODUCTION: Cystic lymphangioma (CL) is a multiloculated congenital malformation of the lymphatic system occurring in approximately 1 in 6,000–12,000 births, and it mostly presents at birth. The CL is of a variable size and it can be found at any age and in any part of the body. This study was carried out to observe the effect of intralesional aqueous bleomycin on giant CL presenting in adult and pediatric cases. MATERIALS AND METHODS: This is an observational study conducted in the department of pediatric surgery and plastic surgery from January 2012 to January 2020. All the diagnosed cases of lymphangioma measuring more than 5 cm in size and managed during this period were reviewed. The cases who had lesions with a vascular component or who had any history of previous surgery or any form of treatment were excluded from the study. A total of 19 cases were included in the study. The primary mode of management of CL at the present center is intralesional bleomycin sclerotherapy (IBS). This is the standard protocol followed at our center to treat the cases with CL. Relevant demographic and clinical data of all the included patients were collected on a structured proforma, and data were analyzed. RESULT: Four cases had a favorable outcome in a single session, seven cases showed a favorable response after the second session, and three cases showed a favorable response after the third session. Two cases showed a partial response even after the fourth session and were considered nonresponders, one of whom was operated on and the other who was satisfied with a partial response and was not willing to undergo surgical excision. No major complications were observed in the present series. A few cases developed mild pain with or without fever, but none of them required hospitalization. CONCLUSION: Intralesional bleomycin sclerotherapy (IBS) is a safe, effective, and economical treatment option for the management of large cystic lymphangiomas and it avoids surgery-related complications. Level of Study: IV evidence study Type of Study: Retrospective observational study Wolters Kluwer - Medknow 2020 /pmc/articles/PMC8061645/ /pubmed/33911413 http://dx.doi.org/10.4103/JCAS.JCAS_108_20 Text en Copyright: © 2020 Journal of Cutaneous and Aesthetic Surgery https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Original Article
Bhatnagar, Ankur
Neyaz, Zafar
Singh, Brajesh
Mishra, Ashwani
Yusuf,
Upadyayaya, Vijai Datta
Kumar, Basant
Bleomycin Sclerotherapy in Massive Macrocystic Lymphatic Malformation: Minimal Complications with Maximum Results
title Bleomycin Sclerotherapy in Massive Macrocystic Lymphatic Malformation: Minimal Complications with Maximum Results
title_full Bleomycin Sclerotherapy in Massive Macrocystic Lymphatic Malformation: Minimal Complications with Maximum Results
title_fullStr Bleomycin Sclerotherapy in Massive Macrocystic Lymphatic Malformation: Minimal Complications with Maximum Results
title_full_unstemmed Bleomycin Sclerotherapy in Massive Macrocystic Lymphatic Malformation: Minimal Complications with Maximum Results
title_short Bleomycin Sclerotherapy in Massive Macrocystic Lymphatic Malformation: Minimal Complications with Maximum Results
title_sort bleomycin sclerotherapy in massive macrocystic lymphatic malformation: minimal complications with maximum results
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8061645/
https://www.ncbi.nlm.nih.gov/pubmed/33911413
http://dx.doi.org/10.4103/JCAS.JCAS_108_20
work_keys_str_mv AT bhatnagarankur bleomycinsclerotherapyinmassivemacrocysticlymphaticmalformationminimalcomplicationswithmaximumresults
AT neyazzafar bleomycinsclerotherapyinmassivemacrocysticlymphaticmalformationminimalcomplicationswithmaximumresults
AT singhbrajesh bleomycinsclerotherapyinmassivemacrocysticlymphaticmalformationminimalcomplicationswithmaximumresults
AT mishraashwani bleomycinsclerotherapyinmassivemacrocysticlymphaticmalformationminimalcomplicationswithmaximumresults
AT yusuf bleomycinsclerotherapyinmassivemacrocysticlymphaticmalformationminimalcomplicationswithmaximumresults
AT upadyayayavijaidatta bleomycinsclerotherapyinmassivemacrocysticlymphaticmalformationminimalcomplicationswithmaximumresults
AT kumarbasant bleomycinsclerotherapyinmassivemacrocysticlymphaticmalformationminimalcomplicationswithmaximumresults